The term incretin was coined by Starling in the early 1900s to mean a gut hormone which stimulates the internal secretion of the pancreas ( The development of DPP-4 inhibition as a glucose-lowering principle started in the 1990s with basic studies, continued in the 2000s with clinical studies for introduction of the concept to the market and was further developed in the 2010s with studies in special groups and long-term outcome studies with focus on cardiovascular diseases
Zepbound is the FDA-approved, brand-name tirzepatide product manufactured by Eli Lilly
mercury, lead, arsenic, cadmium, manganese, and iron
3 Department of Primary Care and Family Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China